User:Mr. Ibrahem/Rivaroxaban
Clinical data | |
---|---|
Trade names | Xarelto, others |
Other names | BAY 59-7939 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611049 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 80–100%; Cmax = 2–4 hours (10 mg oral)[1] |
Metabolism | CYP3A4, CYP2J2 and CYP-independent mechanisms[1] |
Elimination half-life | 5–9 hours in healthy subjects aged 20 to 45[1][2] |
Excretion | 2/3 metabolized in liver and 1/3 eliminated unchanged[1] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C19H18ClN3O5S |
Molar mass | 435.88 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots.[4] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery.[4] It is taken by mouth.[4]
Common side effects include bleeding.[4] Other serious side effects may include spinal hematoma and anaphylaxis.[4] It is unclear if use in pregnancy and breastfeeding is safe.[5] Compared to warfarin it has fewer interactions with other medications.[6] It works by blocking the activity of the clotting protein factor Xa.[4]
Rivaroxaban was patented in 2007 and approved for medical use in the United States in 2011.[7] In the United States, it will not be available as a generic medication until 2024.[8][9] A month supply in the United Kingdom costs the NHS about £50 as of 2020.[10] In the United States, the wholesale cost of this amount is about US$430.[11] In 2017, it was the 109th most commonly prescribed medication in the United States, with more than six million prescriptions.[12][13]
References[edit]
- ^ a b c d "Xarelto: Summary of Product Characteristics". Bayer Schering Pharma AG. 2008. Retrieved 2009-02-11.
- ^ Turgeon, Mary Lou (2018). "28. Disorders of haemostats and thrombosis: blood coagulation factors, hyper coagulable state, and anticoagulant therapy". Clinical Hematology: Theory & Procedures, Enhanced Edition (6th ed.). Burlington: Jones & Bartlett Learning. pp. 575–576. ISBN 978-1-284-29449-1.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 6 September 2020.
- ^ a b c d e f "Rivaroxaban Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- ^ "Rivaroxaban Use During Pregnancy". Drugs.com. Retrieved 3 March 2019.
- ^ Kiser, Kathryn (2017). Oral Anticoagulation Therapy: Cases and Clinical Correlation. Springer. p. 11. ISBN 9783319546438.
- ^ "Generic Xarelto Availability". Drugs.com. Retrieved 9 May 2017.
- ^ "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". www.accessdata.fda.gov. Retrieved 2019-04-24.
- ^ "Bayer, J&J Win Ruling That Upholds Patent for Xarelto Drug". 2019-04-22. Retrieved 2019-04-24.
- ^ BNF (80 ed.). London: BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. pp. 137–139. ISBN 978-0-85711-369-6.
{{cite book}}
: CS1 maint: date format (link) - ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- ^ "Rivaroxaban - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.